Moat Ross
Insider CIK 1857177 · KNSA Chief Commercial Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 1,740 | — | $0 | 3,481 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 2,457 | — | $0 | 7,371 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 2,477 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-09-01 | 2026-09-03 | 9,250 | — | $0 | 9,250 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 1,611 | — | $0 | 1,611 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-09-01 | 2026-09-03 | 36,950 | — | $0 | 36,950 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 2,477 | — | $0 | 14,506 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 1,740 | — | $0 | 17,857 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 2,457 | — | $0 | 20,314 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2026-09-01 | 2026-09-03 | 4,007 | $79.28 | $317.7K | 16,307 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 1,611 | — | $0 | 16,117 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 2,477 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 1,611 | — | $0 | 1,611 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 1,740 | — | $0 | 3,481 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 2,457 | — | $0 | 7,371 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-09-01 | 2026-09-03 | 36,950 | — | $0 | 36,950 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-09-01 | 2026-09-03 | 9,250 | — | $0 | 9,250 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2026-09-01 | 2026-09-03 | 4,007 | $79.28 | $317.7K | 16,307 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 2,457 | — | — | 20,314 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 1,740 | — | — | 17,857 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 1,611 | — | — | 16,117 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 2,477 | — | — | 14,506 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2026-04-09 | 2026-04-13 | 1,703 | $46.69 | $79.5K | 12,029 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-04-07 | 2026-04-08 | 2,477 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-04-07 | 2026-04-08 | 2,477 | — | $0 | 14,506 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2026-04-07 | 2026-04-08 | 774 | $48.94 | $37.9K | 13,732 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2026-04-06 | 2026-04-08 | 2,367 | $48.58 | $115.0K | 12,029 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-04-01 | 2026-04-03 | 1,740 | — | $0 | 3,481 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-04-01 | 2026-04-03 | 2,457 | — | $0 | 7,371 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-04-01 | 2026-04-03 | 1,611 | — | $0 | 1,161 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-04-01 | 2026-04-03 | 18,500 | — | $0 | 18,500 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-04-01 | 2026-04-03 | 9,250 | — | $0 | 9,250 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-04-01 | 2026-04-03 | 36,950 | — | $0 | 36,950 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2026-04-01 | 2026-04-03 | 1,706 | $48.13 | $82.1K | 14,396 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-04-01 | 2026-04-03 | 5,808 | — | $0 | 16,102 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award | 2026-01-15 | 2026-04-03 | 879 | $24.16 | $21.2K | 10,294 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-09-04 | 2025-09-08 | 3,523 | $35.31 | $124.4K | 9,415 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-09-02 | 2025-09-03 | 994 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2025-09-02 | 2025-09-03 | 481 | $34.28 | $16.5K | 12,938 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-09-02 | 2025-09-03 | 994 | — | $0 | 13,419 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-09-01 | 2025-09-03 | 1,741 | — | $0 | 5,221 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-09-01 | 2025-09-03 | 39,364 | — | $0 | 39,364 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-09-01 | 2025-09-03 | 1,611 | — | $0 | 3,222 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-09-01 | 2025-09-03 | 2,477 | — | $0 | 2,477 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-09-01 | 2025-09-03 | 9,828 | — | $0 | 9,828 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-09-01 | 2025-09-03 | 1,741 | — | $0 | 11,156 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-09-01 | 2025-09-03 | 1,611 | — | $0 | 12,767 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-09-01 | 2025-09-03 | 2,477 | — | $0 | 15,244 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2025-09-01 | 2025-09-03 | 2,819 | $33.49 | $94.4K | 12,425 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-06-03 | 2025-06-05 | 27,594 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-06-03 | 2025-06-05 | 27,594 | $13.35 | $368.4K | 37,009 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-06-03 | 2025-06-05 | 27,594 | $29.02 | $800.8K | 9,415 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-05-05 | 2025-05-05 | 6,272 | — | $0 | 27,389 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-05-05 | 2025-05-05 | 6,272 | $17.76 | $111.4K | 15,687 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-05-05 | 2025-05-05 | 6,272 | $28.00 | $175.6K | 9,415 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-05-02 | 2025-05-05 | 3,850 | — | $0 | 33,661 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-05-02 | 2025-05-05 | 3,850 | $28.00 | $107.8K | 9,415 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-05-02 | 2025-05-05 | 3,850 | $17.76 | $68.4K | 13,265 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-05-01 | 2025-05-01 | 1,157 | — | $0 | 37,511 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-05-01 | 2025-05-01 | 8,671 | — | $0 | 21,059 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-05-01 | 2025-05-01 | 13,406 | — | $0 | 27,594 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-05-01 | 2025-05-05 | 8,303 | — | $0 | 8,303 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-05-01 | 2025-05-05 | 8,043 | — | $0 | 8,043 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-05-01 | 2025-05-05 | 5,225 | — | $0 | 5,225 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-05-01 | 2025-05-05 | 4,976 | — | $0 | 4,976 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-05-01 | 2025-05-01 | 13,406 | $13.35 | $179.0K | 22,821 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-05-01 | 2025-05-01 | 8,671 | $11.10 | $96.2K | 31,492 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-05-01 | 2025-05-01 | 1,157 | $17.76 | $20.5K | 32,649 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-05-01 | 2025-05-01 | 23,234 | $28.02 | $651.0K | 9,415 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-04-29 | 2025-05-01 | 6,296 | — | $0 | 1,658 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-04-29 | 2025-05-01 | 15,307 | — | $0 | 23,361 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-04-29 | 2025-05-01 | 15,000 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-04-29 | 2025-05-01 | 20,000 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-04-29 | 2025-05-01 | 7,432 | — | $0 | 27,252 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-04-29 | 2025-05-01 | 64,035 | $25.21 | $1.61M | 9,415 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-04-29 | 2025-05-01 | 15,307 | $10.76 | $164.7K | 73,450 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-04-29 | 2025-05-01 | 6,296 | $12.97 | $81.7K | 50,711 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-04-29 | 2025-05-01 | 20,000 | $15.50 | $310.0K | 44,415 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-04-29 | 2025-05-01 | 15,000 | $15.52 | $232.8K | 24,415 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-04-29 | 2025-05-01 | 7,432 | $11.97 | $89.0K | 58,143 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-04-21 | 2025-04-23 | 18,259 | $20.29 | $370.5K | 9,415 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-04-07 | 2025-04-09 | 2,477 | — | $0 | 2,477 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2025-04-07 | 2025-04-09 | 727 | $20.28 | $14.7K | 27,674 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-04-07 | 2025-04-09 | 2,477 | — | $0 | 28,401 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-04-01 | 2025-04-03 | 1,741 | — | $0 | 5,221 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-04-01 | 2025-04-03 | 1,611 | — | $0 | 3,222 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-04-01 | 2025-04-03 | 19,657 | — | $0 | 19,657 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-04-01 | 2025-04-03 | 9,828 | — | $0 | 9,828 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-04-01 | 2025-04-03 | 39,364 | — | $0 | 39,364 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-04-01 | 2025-04-03 | 1,611 | — | $0 | 25,167 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2025-04-01 | 2025-04-03 | 473 | $21.77 | $10.3K | 26,435 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-04-01 | 2025-04-03 | 1,741 | — | $0 | 26,908 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2025-04-01 | 2025-04-03 | 511 | $21.77 | $11.1K | 25,924 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-03-16 | 2025-03-19 | 994 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-03-16 | 2025-03-19 | 994 | — | $0 | 23,848 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2025-03-16 | 2025-03-19 | 292 | $22.61 | $6.6K | 23,556 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award | 2025-01-15 | 2025-03-19 | 1,118 | $16.00 | $17.9K | 22,854 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2024-09-03 | 2024-09-04 | 29,730 | — | $0 | 18,534 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2024-09-03 | 2024-09-04 | 14,000 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2024-09-03 | 2024-09-04 | 24,776 | — | $0 | 30,924 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2024-09-03 | 2024-09-04 | 67,346 | $26.10 | $1.76M | 22,896 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2024-09-03 | 2024-09-04 | 1,160 | $27.12 | $31.5K | 21,736 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2024-09-03 | 2024-09-04 | 29,730 | $11.10 | $330.0K | 65,466 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2024-09-03 | 2024-09-04 | 14,000 | $8.83 | $123.6K | 35,736 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2024-09-03 | 2024-09-04 | 24,776 | $11.97 | $296.6K | 90,242 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2024-09-02 | 2024-09-04 | 994 | — | $0 | 994 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2024-09-02 | 2024-09-04 | 345 | $26.74 | $9.2K | 21,736 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2024-09-02 | 2024-09-04 | 994 | — | $0 | 22,081 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2024-09-01 | 2024-09-04 | 1,612 | — | $0 | 4,833 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2024-09-01 | 2024-09-04 | 6,962 | — | $0 | 6,962 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2024-09-01 | 2024-09-04 | 2,477 | — | $0 | 4,954 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2024-09-01 | 2024-09-04 | 36,100 | — | $0 | 36,100 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2024-09-01 | 2024-09-04 | 4,089 | — | $0 | 22,480 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2024-09-01 | 2024-09-04 | 1,393 | $26.74 | $37.2K | 21,087 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award | 2024-07-15 | 2024-09-04 | 211 | $15.65 | $3.3K | 18,391 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2024-04-08 | 2024-04-08 | 2,477 | — | $0 | 9,318 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2024-04-08 | 2024-04-08 | 1,353 | $17.90 | $24.2K | 16,276 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2024-04-08 | 2024-04-08 | 2,477 | — | $0 | 17,629 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2024-04-04 | 2024-04-08 | 6,962 | — | $0 | 11,795 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2024-04-04 | 2024-04-08 | 5,569 | — | $0 | 5,569 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2024-04-04 | 2024-04-08 | 36,100 | — | $0 | 36,100 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2024-04-01 | 2024-04-03 | 1,612 | — | $0 | 4,833 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2024-04-01 | 2024-04-03 | 880 | $19.70 | $17.3K | 15,152 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2024-04-01 | 2024-04-03 | 1,612 | — | $0 | 16,032 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2023-09-02 | 2023-09-06 | 994 | — | $0 | 1,988 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2023-09-02 | 2023-09-06 | 543 | $17.76 | $9.6K | 14,420 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2023-09-02 | 2023-09-06 | 994 | — | $0 | 14,963 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2023-09-01 | 2023-09-06 | 2,477 | — | $0 | 7,431 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2023-09-01 | 2023-09-06 | 6,445 | — | $0 | 6,445 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2023-09-01 | 2023-09-06 | 38,668 | — | $0 | 38,668 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2023-09-01 | 2023-09-06 | 1,353 | $17.76 | $24.0K | 13,969 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2023-09-01 | 2023-09-06 | 2,477 | — | $0 | 15,322 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award | 2023-07-15 | 2023-09-06 | 292 | $12.35 | $3.6K | 12,845 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2023-04-10 | 2023-04-11 | 2,477 | — | $0 | 7,431 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2023-04-10 | 2023-04-11 | 2,477 | — | $0 | 13,906 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2023-04-10 | 2023-04-11 | 1,353 | $10.71 | $14.5K | 12,553 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2023-04-01 | 2023-04-03 | 38,668 | — | $0 | 38,668 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2023-04-01 | 2023-04-03 | 6,445 | — | $0 | 6,445 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2023-03-20 | 2023-03-20 | 2,137 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2023-03-20 | 2023-03-20 | 1,167 | $11.12 | $13.0K | 11,429 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2023-03-20 | 2023-03-20 | 2,137 | — | $0 | 12,596 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2023-03-16 | 2023-03-20 | 994 | — | $0 | 1,988 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2023-03-16 | 2023-03-20 | 994 | — | $0 | 11,002 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2023-03-16 | 2023-03-20 | 543 | $11.46 | $6.2K | 10,459 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award | 2023-01-15 | 2023-03-20 | 1,844 | $9.56 | $17.6K | 10,008 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2022-09-02 | 2022-09-06 | 995 | — | $0 | 2,982 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2022-09-02 | 2022-09-06 | 563 | $11.44 | $6.4K | 8,164 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2022-09-02 | 2022-09-06 | 995 | — | $0 | 8,727 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2022-09-01 | 2022-09-06 | 59,460 | — | $0 | 59,460 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2022-09-01 | 2022-09-06 | 9,908 | — | $0 | 9,908 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award | 2022-07-15 | 2022-09-06 | 360 | $9.56 | $3.4K | 7,732 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2022-04-07 | 2022-04-11 | 9,908 | — | $0 | 9,908 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2022-04-07 | 2022-04-11 | 59,460 | — | $0 | 59,460 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2022-03-21 | 2022-03-23 | 2,270 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2022-03-21 | 2022-03-23 | 1,240 | $10.98 | $13.6K | 7,372 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2022-03-21 | 2022-03-23 | 2,270 | — | $0 | 8,612 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2022-03-16 | 2022-03-18 | 995 | — | $0 | 2,982 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2022-03-16 | 2022-03-18 | 995 | — | $0 | 6,886 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2022-03-16 | 2022-03-18 | 544 | $10.13 | $5.5K | 6,342 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award | 2022-01-15 | 2022-03-18 | 1,546 | $9.63 | $14.9K | 5,891 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2021-09-02 | 2021-09-07 | 7,954 | — | $0 | 7,954 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2021-09-02 | 2021-09-07 | 3,977 | — | $0 | 3,977 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award | 2021-07-15 | 2022-03-18 | 963 | $11.49 | $11.1K | 4,345 | SEC↗ |